-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY), Acceleron (XLRN) Announce Reblozyl Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at ASH
-
-
-
-
-
-
-
Celgene (CELG), Acceleron Pharma (XLRN) Announce FDA Accepts Luspatercept BLA in Myelodysplastic Syndromes and Beta-Thalassemia
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

